Drug intelligence / Profile preview

CR-004

Development stage: Preclinical
Lead developer: Crescent Biopharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CR-004 is an antibody-drug conjugate (ADC) currently in the discovery phase of development by Crescent Biopharma. It is being investigated for the treatment of various solid tumors. As of early 2024, the specific molecular target and the cytotoxic payload of the conjugate remain undisclosed by the developer. The program is part of Crescent Biopharma's oncology pipeline, which focuses on advancing next-generation targeted biologics and precision medicine.

Other names: CR-004-Cresence-ADC-solid tumorsCR004-Cresence-ADC-solid tumorsCR 004-Cresence-ADC-solid tumors

Beyond the preview

Go deeper on CR-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR-004.

Explore the full profile